Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study in Greece

Τzouvelekis, Αrgyris; Karampitsakos, Theodoros; Gomatou, Georgia; Bouros, Evangelos; Tzilas, Vasilios; Manali, Efrosini; Tomos, Ioannis; Trachalaki, Athina; Kolilekas, Lykourgos; Korbila, Ioanna; Tomos, Periklis; Chrysikos, Serafeim; Gaga, Mina; Daniil, Zoe; Bardaka, Fotini; Papanikolaou, Ilias; Euthymiou, Christopher; Papakosta, Despoina; Steiropoulos, Paschalis; Ntolios, Paschalis; Tringidou, Rodoula; Papiris, Spyridon; Αντωνίου, Κατερίνα; Bouros, Demosthenes

doi:10.1016/j.pupt.2019.101880

Cited by 40 publications

(25 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gibiot et al [ 6 ], found median survival of 9 months for patients with lung cancer and ILD as opposed to 18 months for those with lung cancer only. Tzouvelekis et al [ 12 ], recently reported a median survival of 14 months in patients with lung cancer and IPF from the time of lung cancer diagnosis. Sekihara et al [ 13 ], reported 5 year-overall survival of 40% in patients with lung cancer and ILD as opposed to 72% in those with lung cancer only without ILD.…”

Section: Discussionmentioning

confidence: 99%

“…Official guidelines about the most appropriate chemotherapeutic plan for patients with IPF and lung cancer are lacking [ 16 ]. Chemotherapeutic regimens except for carboplatin have been reported to increase pulmonary toxicity in patients with IPF [ 12 , 17 ]. Radiation therapy may also prove detrimental rather than beneficial for some patients with lung cancer and IPF.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Survival analysis in lung cancer patients with interstitial lung disease

et al. 2021

View full text Add to dashboard Cite

Objective Lung cancer patients with interstitial lung disease (ILD) are prone for higher morbidity and mortality and their treatment is challenging. The purpose of this study is to investigate whether the survival of lung cancer patients is affected by the presence of ILD documented on CT. Materials and methods 146 patients with ILD at initial chest CT were retrospectively included in the study. 146 lung cancer controls without ILD were selected. Chest CTs were evaluated for the presence of pulmonary fibrosis which was classified in 4 categories. Presence and type of emphysema, extent of ILD and emphysema, location and histologic type of cancer, clinical staging and treatment were evaluated. Kaplan-Meier estimates and Cox regression models were used to assess survival probability and hazard of death of different groups. P value < 0.05 was considered significant. Results 5-year survival for the study group was 41% versus 48% for the control group (log-rank test p = 0.0092). No significant difference in survival rate was found between the four different categories of ILD (log-rank test, p = 0.195) and the different histologic types (log-rank test, p = 0.4005). A cox proportional hazard model was used including presence of ILD, clinical stage and age. The hazard of death among patients with ILD was 1.522 times that among patients without ILD (95%CI, p = 0.029). Conclusion Patients with lung cancer and CT evidence of ILD have a significantly shorter survival compared to patients with lung cancer only. Documenting the type and grading the severity of ILD in lung cancer patients will significantly contribute to their challenging management.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Survival analysis in lung cancer patients with interstitial lung disease

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Several studies have reported survival in patients with SCLC and IPF. 6 , 9 – 13 Based on these data sets ( n = 10–59), overall survival (OS) was reportedly around 7–16 months. On the other hand, it has been reported that the response rate to first-line chemotherapy was not different between patients with ILD ( n = 28) and non-ILD patients.…”

Section: Introductionmentioning

confidence: 99%

“… 13 In cases of SCLC with underlying IPF, the efficacy and safety of chemotherapy and chemoradiotherapy are largely unknown as well. 10 – 13 …”

Section: Introductionmentioning

confidence: 99%

Clinical features of patients with small cell lung cancer and idiopathic pulmonary fibrosis treated with chemotherapy or chemoradiotherapy

Kanaji

Shimizu

Sakai

et al. 2020

Ther Adv Respir Dis

View full text Add to dashboard Cite

Background: The clinical features of patients with small cell lung cancer (SCLC) and idiopathic pulmonary fibrosis (IPF) have not been fully elucidated. Patients and methods: Data on 366 patients with pathologically confirmed SCLC who had been treated with chemotherapy or chemoradiotherapy were retrospectively analyzed to investigate the clinical features of SCLC with IPF. Results: A total of 97 out of the 366 patients were diagnosed with interstitial lung disease (ILD), and 75 of them had IPF. For both the limited disease (LD) and extensive disease (ED) stages, the median progression-free survival (PFS) and overall survival (OS) were significantly shorter in the patients with IPF compared with non-ILD patients. A multivariate analysis showed that poor performance status, ED stage, and the presence of IPF were associated with shorter OS. The response rate to first-line therapy was significantly lower in patients with IPF compared with the non-ILD patients. The rate of patients receiving fewer than three cycles of first-line chemotherapy was higher in patients with IPF, which was a factor of poor survival. In LD-stage patients with IPF, chemoradiotherapy was associated with longer PFS and OS compared with chemotherapy only. Conclusion: In patients with SCLC, the presence of IPF was associated with a lower response rate as well as shorter PFS and shorter OS. There are some cases that are suitable for chemoradiotherapy, even among patients with IPF. The reviews of this paper are available via the supplemental material section.

show abstract

“…it occupies the peripheral fields, especially in the inferior lobes. Unlike in the general population, squamous cell carcinoma is more common than adenocarcinoma [56,57]. Lung cancer significantly worsens the prognosis of patients with IPF, with a 7-fold increased risk of death [58].…”

Section: Nintedanib In the Population Of Ipf Patients With Lung Cancermentioning

confidence: 99%

Nintedanib—Efficacy, Safety and Practical Aspects of Treatment for Patients with Idiopathic Pulmonary Fibrosis

Martusewicz-Boros¹,

Górska

2020

Advances in Respiratory Medicine

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is a rare disease with progressive course and a very unfavourable prognosis. Antifibrotic drugs are a chance to reduce the rate of disease progression and extend the life of IPF patients. One of these drugs is nintedanib, an oral tyrosine kinase inhibitor. In the following article, the reader will find a summary of current knowledge on the efficacy and safety of nintedanib treatment of IPF patients. This study uses data from pivotal studies and experience from everyday clinical practice indicating a wide range of possible applications of the drug in IPF patients.

show abstract

Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study in Greece

Cited by 40 publications

References 38 publications

Survival analysis in lung cancer patients with interstitial lung disease

Survival analysis in lung cancer patients with interstitial lung disease

Clinical features of patients with small cell lung cancer and idiopathic pulmonary fibrosis treated with chemotherapy or chemoradiotherapy

Nintedanib—Efficacy, Safety and Practical Aspects of Treatment for Patients with Idiopathic Pulmonary Fibrosis

Contact Info

Product

Resources

About